Neurocrine Biosciences IncHere is the public summary page for Neurocrine Biosciences Inc. Please login to see the complete information for Neurocrine Biosciences Inc including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how Neurocrine Biosciences Inc stacks up relative to its peers. |
| Darwin Score | +27 |
| Ticker | NBIX |
| Latest Price | 133.48 USD as of close on 16-Jul-2025 |
| 3 Month price range | 100.68 to 135.13 USD |
| Market Capitalisation | 12.99Bn USD |
| Country | United States of America |
| Region | North America |
| Economic Sector | Health Care |
| Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Sub-Industry | Biotechnology |
| Description | Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. See More ... |
| Company URL | https://www.neurocrine.com |
| See Darwins Full Analysis for Neurocrine Biosciences Inc |
Tell Me About
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Neurocrine Biosciences Inc. Further information and full detail is available when you login.
| TMA Part | Focus of Analysis | TMA Score |
|---|---|---|
| Price | Analysis of performance, trend, RSI, OBV and moving averages | +26 |
| Sentiment | News and Candle Patterns. | -2 |
| Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | +2 |
| Flow | Institutional, Fund and Insider buying and selling. | -8 |
| Models | Forecast models. | +9 |
Alerts
There are 6 live alerts for Neurocrine Biosciences Inc.
- Overbought - The 5 month RSI is +70.6. (Negative)
- Candle Pattern :: Engulfing (Negative) (Negative) (Negative)
- Price crossing down through 5 day SMA. This alert has occurred 29 times over the last last year. The average forward returns are 0.4% over 5 days, -0.7% over 10 days, 0.2% over 15 days and 0.1% over 20 days. (Positive)
- Divergence: Px Up & 30d RSI Down last 20 days. This alert has occurred 26 times over the last last year. The average forward returns are 0.1% over 5 days, -1.7% over 10 days, -4.3% over 15 days and -6.3% over 20 days. (Negative)
- Cross Over (Down): 5dma . This alert has occurred 29 times over the last last year. The average forward returns are 0.4% over 5 days, -0.7% over 10 days, 0.2% over 15 days and 0.1% over 20 days. (Negative)
- Divergence: Px Up & 15d RSI Down last 20 days. This alert has occurred 45 times over the last last year. The average forward returns are 0.4% over 5 days, 0.1% over 10 days, -0.9% over 15 days and -1.9% over 20 days. (Negative)
Peer Comparison
There are 22 peers of Neurocrine Biosciences Inc.
| Asset Name | Industry Group | Asset Score |
|---|---|---|
| ACADIA Pharmaceuticals Inc (ACAD) | Biotechnology | +23 |
| Amgen Inc (AMGN) | Biotechnology | +42 |
| Arrowhead Pharmaceuticals Inc (ARWR) | Biotechnology | +9 |
| BioMarin Pharmaceutical Inc (BMRN) | Biotechnology | -5 |
| Biogen Inc (BIIB) | Biotechnology | -8 |
| Black Diamond Therapeutics Inc (BDTX) | Biotechnology | +5 |
| Dynavax Technologies Corp (DVAX) | Biotechnology | -4 |
| Exelixis Inc (EXEL) | Biotechnology | +43 |
| FibroGen Inc (FGEN) | Biotechnology | +1 |
| Gilead Sciences Inc (GILD) | Biotechnology | +11 |
| Halozyme Therapeutics Inc (HALO) | Biotechnology | +21 |
| Humacyte Inc (HUMA) | Biotechnology | -29 |
| Incyte Corp (INCY) | Biotechnology | -6 |
| Krystal Biotech Inc (KRYS) | Biotechnology | +3 |
| MacroGenics Inc (MGNX) | Biotechnology | -24 |
| Moderna Inc (MRNA) | Biotechnology | -7 |
| Myriad Genetics Inc (MYGN) | Biotechnology | -25 |
| OPKO Health Inc (OPK) | Biotechnology | -5 |
| Regeneron Pharmaceuticals Inc (REGN) | Biotechnology | -9 |
| United Therapeutics Corp (UTHR) | Biotechnology | -10 |
| Vertex Pharmaceuticals Inc (VRTX) | Biotechnology | +12 |
| Vir Biotechnology Inc (VIR) | Biotechnology | -23 |
Share 
